Testing EC5026 for Parkinson's disease
Treatments studied
Part of Brain & nervous system clinical trials.
This study tests a new oral medication called EC5026 for Parkinson's disease. It aims to see if the drug is safe and if it might help control symptoms when added to your current levodopa treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 80 years old.
- You have been diagnosed with Parkinson's disease by a doctor.
- You are taking levodopa (Sinemet or Madopar) and have been on the same dose for at least 30 days.
- You are able to walk and move around without help (your Parkinson's is not too advanced).
- You do not have dementia, hallucinations, or other serious mental health problems.
- You have not had brain surgery for Parkinson's (like deep brain stimulation).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication for people with early-onset Parkinson's disease. It aims to see if the drug safely improves motor symptoms and quality of life compared to a placebo.
This study tests a new tablet called ENERGI-F705 to see if it helps reduce Parkinson's disease symptoms and is safe to take. You'll need to have had Parkinson's for at least 2 years and be on standard Parkinson's medications.
This trial tests a new tablet (VG081821AC) for people with early-to-mid-stage Parkinson's disease who have not recently used levodopa. The goal is to see if it can improve movement symptoms safely.
This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.
This study tests an investigational drug to see if it can help people with early Parkinson's disease. It may offer a new treatment option to manage symptoms.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
Hear when a new Parkinson's Disease (PD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.